PACTR201202000356208Other未知
Efficacy Study of ChAd63-MVA ME-TRAP prime-boost Vaccination against Plasmodium falciparum infection
适应症
试验速览
- 阶段
- 未知
- 状态
- Other
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 50 Year(s)（—）
- 性别
- Male
入选标准
- •Consenting adult males aged 18 ¿ 50 years in good health.
- •Will remain resident in the study area for the study duration.
- •Able and willing (in the Investigator¿s opinion) to comply with all study requirements
- •Informed Consent
排除标准
- •¿Any significant medical disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
- •¿Hypersensitivity to HDCRV,the trial vaccines or the antimalarial used.
- •¿History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. egg products, kathon, neomycin
- •¿History of splenectomy.
- •¿Haemoglobin less than 10.0 g/dl
- •¿Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels).
- •¿Blood transfusion within the month preceding enrolment.
- •¿History of vaccination with previous experimental malaria vaccines or other vaccines likely to impact on findings of study (e.g. other MVA or adenovirus vectored vaccines)
- •¿Administration of any other vaccine or immunoglobulin within 2 weeks before vaccination.
- •¿HIV or Hepatitis B surface antigen seropositivity.
- •¿Current participation in another clinical trial or recent participation within 12 weeks of this study.
- •¿Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.
- •¿Likelihood of travel away from the study area
研究者
相似试验
已完成
不适用
Efficacy Study of ChAd63-MVA ME-TRAP prime-boost Vaccination against PlasmodiumMalariaPACTR201303000499409niversity of Oxford160
招募中
1 期
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.MedDRA version: 27.0Level: PTClassification code: 10066264Term: Acute graft versus host disease in intestine Class: 100000004870CTIS2024-513023-17-00MaaT PHARMA73
招募中
1 期
Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trialSalvage therapy of acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib.MedDRA version: 27.0Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersEUCTR2021-001841-11-ATMaaT Pharma75
进行中（未招募）
1 期
Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trialEUCTR2021-001841-11-ESMaaT Pharma75
已完成
1 期
A study to test three experimental HIV vaccines in healthy adultsHIV/AIDSPACTR202006495409011niversity of Oxford88